Ascentage Pharma Updates AGM Date for RSU and Option Mandate Clarification

Bulletin Express

Jul 13

Ascentage Pharma Group International announced a clarification regarding its previously disclosed equity incentive plans. The company confirmed that the annual general meeting (AGM) at which shareholders approved the scheme mandate limits for the 2021 Restricted Share Unit (RSU) Scheme, the 2022 RSU Scheme, and the Post-IPO Share Option Scheme took place on 19 May 2025, not 20 May 2026 as earlier stated.

All other details in the 29 June 2026 announcement—covering additional grants of RSUs and options under the respective schemes—remain unchanged. The correction solely addresses the AGM date reference to ensure procedural accuracy for satisfying the newly granted awards and options.

The board composition is unchanged, led by Chairman and Executive Director Dr. Yang Dajun, alongside two non-executive directors and six independent non-executive directors. The company emphasised that this update should be read in conjunction with the original 29 June 2026 announcement, with no further amendments required.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1103987577"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1103987577\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1103987577?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-13 08:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103987577","market":"hk","top_or_hot":-1,"title":"Ascentage Pharma Updates AGM Date for RSU and Option Mandate Clarification","media":"Bulletin Express","content":"<p>Ascentage Pharma Group International announced a clarification regarding its previously disclosed equity incentive plans. The company confirmed that the annual general meeting (AGM) at which shareholders approved the scheme mandate limits for the 2021 Restricted Share Unit (RSU) Scheme, the 2022 RSU Scheme, and the Post-IPO Share Option Scheme took place on 19 May 2025, not 20 May 2026 as earlier stated.</p>\n<p>All other details in the 29 June 2026 announcement—covering additional grants of RSUs and options under the respective schemes—remain unchanged. The correction solely addresses the AGM date reference to ensure procedural accuracy for satisfying the newly granted awards and options.</p>\n<p>The board composition is unchanged, led by Chairman and Executive Director Dr. Yang Dajun, alongside two non-executive directors and six independent non-executive directors. The company emphasised that this update should be read in conjunction with the original 29 June 2026 announcement, with no further amendments required.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascentage Pharma Updates AGM Date for RSU and Option Mandate Clarification</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscentage Pharma Updates AGM Date for RSU and Option Mandate Clarification\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-13 08:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ascentage Pharma Group International announced a clarification regarding its previously disclosed equity incentive plans. The company confirmed that the annual general meeting (AGM) at which shareholders approved the scheme mandate limits for the 2021 Restricted Share Unit (RSU) Scheme, the 2022 RSU Scheme, and the Post-IPO Share Option Scheme took place on 19 May 2025, not 20 May 2026 as earlier stated.</p>\n<p>All other details in the 29 June 2026 announcement—covering additional grants of RSUs and options under the respective schemes—remain unchanged. The correction solely addresses the AGM date reference to ensure procedural accuracy for satisfying the newly granted awards and options.</p>\n<p>The board composition is unchanged, led by Chairman and Executive Director Dr. Yang Dajun, alongside two non-executive directors and six independent non-executive directors. The company emphasised that this update should be read in conjunction with the original 29 June 2026 announcement, with no further amendments required.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06855","symbol_name":"亚盛医药","start_time":0,"source_url":"","article_id":"1103987577","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103987577","pubTimestamp":1783902107,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Ascentage Pharma Group International announced a clarification regarding its previously disclosed equity incentive plans. The company confirmed that the annual general meeting (AGM) at which...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06855":"亚盛医药"},"translate_title":"Ascentage Pharma 更新 RSU 和期权授权澄清的年度股东大会日期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06855":1},"content_text":"Ascentage Pharma Group International announced a clarification regarding its previously disclosed equity incentive plans. The company confirmed that the annual general meeting (AGM) at which shareholders approved the scheme mandate limits for the 2021 Restricted Share Unit (RSU) Scheme, the 2022 RSU Scheme, and the Post-IPO Share Option Scheme took place on 19 May 2025, not 20 May 2026 as earlier stated.\nAll other details in the 29 June 2026 announcement—covering additional grants of RSUs and options under the respective schemes—remain unchanged. The correction solely addresses the AGM date reference to ensure procedural accuracy for satisfying the newly granted awards and options.\nThe board composition is unchanged, led by Chairman and Executive Director Dr. Yang Dajun, alongside two non-executive directors and six independent non-executive directors. The company emphasised that this update should be read in conjunction with the original 29 June 2026 announcement, with no further amendments required.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}